We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sequencing-Based Testing Sector Already Highly Competitive

By LabMedica International staff writers
Posted on 22 Mar 2015
Print article
As next-generation sequencing (NGS) reaches the clinical laboratory, a new analysis by Kalorama Information (New York, NY, USA) finds that small reference laboratories as well as over 50 companies now offer sequencing-based testing through their own CLIA-certified laboratories, some of which offer a wide range of tests.

“These firms and reference laboratories offer next-gen sequencing that they perform and charge for as a service,” said Bruce Carlson, Kalorama publisher. [Tests for presence of or] “Increased risk for breast and colon cancers, childhood epilepsy, renal disorders, prenatal tests, and many others are available now.” The new report, “Next Generation Sequencing Markets 2015,” features detailed information on top market competitors.

The large amounts of sequence date generated by NGS research can be valuable for trying to answer many questions regarding the genome and disease, but initially cannot be used by clinicians in making treatment decisions. Kalorama notes that diagnostic companies have realized the importance of more targeted approaches focusing on gene mutations with known clinical utility. In addition, sequencing platforms have traditionally been expensive, and using these instruments to test samples has been complex – with requirements for sample preparation, sequencing, and results analysis and interpretation. This has made it difficult to follow the traditional in vitro diagnostic (IVD) approach of developing kits that can be sold to clinical laboratories that would perform the tests. As a result, diagnostic sequencing has generally been performed by clinical laboratories or by companies that establish their own CLIA-certified laboratory.

Kalorama’s report provides details on NGS test offerings of each company as well as detailed tables indicating activities of competitors. The report breaks out system, consumable, and service segments, and provides information on brand ownership and regional installed base of sequencers.

Related Links:

Kalorama Information
Next Generation Sequencing Markets 2015, report


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Tabletop Centrifuge
Mikro 185
New
Automatic Biochemistry Analyzer
Audmax 180 Evolution

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.